Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular

In brief

The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.

Key facts

Study ID

NCT00060684

Run by

CTI BioPharma

People needed

30

Starts

2001-12-01

Expected to finish

2007-05-01

Last updated by the study team

2015-01-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with relapsed or refractory indolent (low-grade) NHL
• Who have received 1-3 prior treatments with chemotherapy

You may not qualify if…

• Patients previously treated with fludarabine
• Prior treatment with rituximab (Rituxan), unless there was a complete response (CR) or partial response (PR) to that treatment
• Patients known to have an allergic reaction to rituximab, or to murine proteins.

Where it is running

• Arizona Clinical Research Center — Tucson, Arizona, United States
• Greater Baltimore Medical Center — Baltimore, Maryland, United States
• New Mexico Onc/Hem Consultants, Inc. — Albuquerque, New Mexico, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.